Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Ultragenyx Pharma (RARE) Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance
July 28, 2022 4:42 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($2.26), $0.51 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $89.3 million versus the consensus estimate of $87.65 million.
GUIDANCE:
Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260... More
